These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27978984)

  • 1. Translational PK/PD modeling to increase probability of success in drug discovery and early development.
    Lavé T; Caruso A; Parrott N; Walz A
    Drug Discov Today Technol; 2016; 21-22():27-34. PubMed ID: 27978984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics/pharmacodynamics model-supported early drug development.
    Chen B; Dong JQ; Pan WJ; Ruiz A
    Curr Pharm Biotechnol; 2012 Jun; 13(7):1360-75. PubMed ID: 22201585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling and Simulation of In Vivo Drug Effects.
    Lippert J; Burghaus R; Kuepfer L; Ploeger B; Schaller S; Schmitt W; Willmann S
    Handb Exp Pharmacol; 2016; 232():313-29. PubMed ID: 26578524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety.
    Reichel A; Lienau P
    Handb Exp Pharmacol; 2016; 232():235-60. PubMed ID: 26330260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
    Singh AP; Shin YG; Shah DK
    Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
    Agoram BM; Martin SW; van der Graaf PH
    Drug Discov Today; 2007 Dec; 12(23-24):1018-24. PubMed ID: 18061880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
    Zhao L; Shang EY; Sahajwalla CG
    J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology.
    Garralda E; Dienstmann R; Tabernero J
    Am Soc Clin Oncol Educ Book; 2017; 37():210-215. PubMed ID: 28561730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.
    Chien JY; Friedrich S; Heathman MA; de Alwis DP; Sinha V
    AAPS J; 2005 Oct; 7(3):E544-59. PubMed ID: 16353932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-Based Virtual PK/PD Exploration and Machine Learning Approach to Define PK Drivers in Early Drug Discovery.
    Chen EP; Dutta S; Ho MH; DeMartino MP
    J Med Chem; 2024 Mar; 67(5):3727-3740. PubMed ID: 38375820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.
    Ploeger BA; van der Graaf PH; Danhof M
    Drug Metab Pharmacokinet; 2009; 24(1):3-15. PubMed ID: 19252332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.
    Wong H; Bohnert T; Damian-Iordache V; Gibson C; Hsu CP; Krishnatry AS; Liederer BM; Lin J; Lu Q; Mettetal JT; Mudra DR; Nijsen MJMA; Schroeder P; Schuck E; Suryawanshi S; Trapa P; Tsai A; Wang H; Wu F
    Drug Discov Today; 2017 Oct; 22(10):1447-1459. PubMed ID: 28476536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA).
    Goto A; Abe S; Koshiba S; Yamaguchi K; Sato N; Kurahashi Y
    Drug Metab Pharmacokinet; 2019 Apr; 34(2):148-154. PubMed ID: 30827921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Automated analysis of routinely generated preclinical pharmacokinetic and pharmacodynamic data.
    Lindhardt E; Gennemark P
    J Bioinform Comput Biol; 2014 Jun; 12(3):1450010. PubMed ID: 24969748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses.
    Kielbasa W; Stratford RE
    Drug Metab Dispos; 2012 May; 40(5):877-83. PubMed ID: 22287668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics.
    van den Brink WJ; Hankemeier T; van der Graaf PH; de Lange ECM
    Expert Opin Drug Discov; 2018 Jun; 13(6):539-550. PubMed ID: 29519169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Modeling and Simulation in the Development of Novel and Biosimilar Therapeutic Proteins.
    Wang YC; Wang Y; Schrieber SJ; Earp J; Thway TM; Huang SM; Zineh I; Christl L
    J Pharm Sci; 2019 Jan; 108(1):73-77. PubMed ID: 30395832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
    Bellissant E; Courcier-Duplantier S; Blin O;
    Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.